The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jefferies Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $50
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $39
Scholar Rock Advances With Promising SMA Trial Results